Page last updated: 2024-12-11

myxothiazol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

myxothiazol: strobilurin analogue; methoxyacrylamide derivative; antifungal antibiotic from Myxococcus fulvus; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

myxothiazol : A 2,4'-bi-1,3-thiazole substituted at the 4-position with a (1E,3S,4R,5E)-7-amino-3,5-dimethoxy-4-methyl-7-oxohepta-1,5-dien-1-yl] group and at the 2'-position with a (2S,3E,5E)-7-methylocta-3,5-dien-2-yl group. It is an inhibitor of coenzyme Q - cytochrome c reductase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6437357
CHEBI ID25461
SCHEMBL ID4361094
MeSH IDM0096462

Synonyms (7)

Synonym
myxothiazol
(+)-myxothiazol
(2e,4r,5s,6e)-3,5-dimethoxy-4-methyl-7-{2'-[(2s,3e,5e)-7-methylocta-3,5-dien-2-yl]-2,4'-bi-1,3-thiazol-4-yl}hepta-2,6-dienamide
CHEBI:25461
SCHEMBL4361094
(2e,4r,5s,6e)-3,5-dimethoxy-4-methyl-7-[2-[2-[(3e,5e)-7-methylocta-3,5-dien-2-yl]-1,3-thiazol-4-yl]-1,3-thiazol-4-yl]hepta-2,6-dienamide
Q6949371

Research Excerpts

Overview

Mexothiazol is a respiratory chain complex III (CIII) inhibitor. It binds to the ubiquinol oxidation site Qo of CIII.

ExcerptReferenceRelevance
"Myxothiazol is a respiratory chain complex III (CIII) inhibitor that binds to the ubiquinol oxidation site Qo of CIII. "( A mouse model of mitochondrial complex III dysfunction induced by myxothiazol.
Davoudi, M; Fellman, V; Hansson, E; Kallijärvi, J; Kotarsky, H; Levéen, P; Marjavaara, S, 2014
)
2.08

Treatment

Treatment with myxothiazol alone at concentrations that significantly inhibit respiration dramatically increased the steady-state levels of ROS in hepatocytes. When myxOTHiazol treatment was combined with moderately reduced O(2) delivery, V(O(2))(,max) was reduced by an additional 18 % (484 +/- 21 micromol O( 2) min(-1) (100 g)(-1)); P < 0.05)

ExcerptReferenceRelevance
"When myxothiazol treatment was combined with moderately reduced O(2) delivery, V(O(2))(,max) was reduced by an additional 18 % (484 +/- 21 micromol O(2) min(-1) (100 g)(-1)); P < 0.05) compared to either intervention performed independently."( Oxidative capacity interacts with oxygen delivery to determine maximal O(2) uptake in rat skeletal muscles in situ.
Hagen, JL; Hepple, RT; Krause, DJ, 2002
)
0.77
"Treatment with myxothiazol alone at concentrations that significantly inhibit respiration dramatically increased the steady-state levels of ROS in hepatocytes."( Reactive oxygen species production by the mitochondrial respiratory chain in isolated rat hepatocytes and liver mitochondria: studies using myxothiazol.
Bailey, SM; Cunningham, CC; Young, TA, 2002
)
0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (2)

PathwayProteinsCompounds
NADH to cytochrome bo oxidase electron transfer I1734
NADH to cytochrome bd oxidase electron transfer I1627

Research

Studies (266)

TimeframeStudies, This Drug (%)All Drugs %
pre-199049 (18.42)18.7374
1990's76 (28.57)18.2507
2000's100 (37.59)29.6817
2010's33 (12.41)24.3611
2020's8 (3.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.73 (24.57)
Research Supply Index5.62 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index42.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (1.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other272 (98.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]